Biosion, In Global For Global, antibody-drug conjugate, bosakitug TSLP, SynTracer+Flexibody+H3

English

WELCOME TO BIOSION

Biosion is a global biotechnology company that is currently in the clinical stage.

Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases. Leveraging its proprietary technologies such as the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform, Biosion creates highly differentiated medicines to address significant unmet medical needs worldwide.

PARTNERING

In Global For Global

NEWS

News and Information

Spot the chance with global eyes, Meet unmet needs where healing lies.

Professional quality

2022-04-06

Biosion monoclonal antibody therapies to be featured at the American Association for Cancer Research (AACR) meeting 2022

2022-04-06

Biosion monoclonal antibody therapies to be featured at the American Association for Cancer Research (AACR) meeting 2022

Biosion, Inc. (“Biosion”), a global R&D stage biotechnology company， announced today the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-060T: anti-siglec-15 antibody and BSI-082: anti-SIRP antibody, at the American Association for Cancer Research (AACR) Annual

2021-12-13

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

2021-12-13

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

This license agreement continues to build on Biosion’s efforts to create and develop meaningful biologics to treat resistant, relapsed and residual disease for patients worldwide.

2022-03-30

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology

2022-03-30

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology

Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody; Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned upon advancement of PYX-106

Find us in China, the United States & Australia

Quick Links